Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 19/20 | 0.71 |
| ▸ | ITGAV | P06756 | 16/20 | 0.71 |
| ▸ | ITGA2B | P08514 | 13/20 | 0.71 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.54 |
| ▸ | F2R | P25116 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2924578 | 0.86 | ITGB3 (0.75) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| SCHEMBL13344593 | 0.84 | ITGB3 (0.71) | ITGB3ITGAVITGA2BITGB5F2R | |
| SCHEMBL13344605 | 0.83 | ITGB3 (0.72) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| SCHEMBL2922341 | 0.83 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB5F2R | |
| SCHEMBL3539083 | 0.82 | ITGB3 (0.77) | ITGB3ITGAVITGA2BITGB5F2R | |
| SCHEMBL2924877 | 0.79 | ITGB3 (0.66) | ITGB3ITGAVITGA2B | |
| SCHEMBL2905930 | 0.77 | ITGB3 (0.85) | ITGB3ITGAVITGA2BF2R | |
| SCHEMBL13344630 | 0.75 | ITGB3 (0.54) | ITGB3ITGAVITGA2B | |
| SCHEMBL3534841 | 0.75 | ITGB3 (0.60) | ITGB3ITGAVITGA2BITGB5F2R | |
| SCHEMBL13344588 | 0.74 | ITGB3 (0.59) | ITGB3ITGAVITGA2BITGB5F2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718673-B2 | Isonipecotamides for the treatment of integrin-mediated disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2010-05-18 | — | — | US | claimed |
| EP-1133489-B9 | ISONIPECOTAMIDES FOR THE TREATMENT OF INTEGRIN-MEDIATED DISORDERS | ORTHO MCNEIL PHARM INC (US) | 2006-05-03 | — | — | EP | claimed |
| EP-1133489-B1 | ISONIPECOTAMIDES FOR THE TREATMENT OF INTEGRIN-MEDIATED DISORDERS | ORTHO MCNEIL PHARM INC (US) | 2005-07-27 | — | — | EP | claimed |
| EP-1533310-A1 | Isonipecotamides for the treatment of integrin-mediated disorders | Ortho-McNeil Pharmaceutical, Inc. (US) | 2005-05-25 | — | — | EP | claimed |
| US-20030181440-A1 | Isonipecotamides for the treatment of integrin-mediated disorders | COSTANZO MICHAEL J (US) | 2003-09-25 | — | — | US | claimed |
| US-7718673-B2 | Isonipecotamides for the treatment of integrin-mediated disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718673-B2 | Isonipecotamides for the treatment of integrin-mediated disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718673-B2 | Isonipecotamides for the treatment of integrin-mediated disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| EP-1133489-B9 | ISONIPECOTAMIDES FOR THE TREATMENT OF INTEGRIN-MEDIATED DISORDERS | ORTHO MCNEIL PHARM INC (US) | 2006-05-03 | — | — | EP | disclosed |
| EP-1133489-B1 | ISONIPECOTAMIDES FOR THE TREATMENT OF INTEGRIN-MEDIATED DISORDERS | ORTHO MCNEIL PHARM INC (US) | 2005-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181440-A1 | Isonipecotamides for the treatment of integrin-mediated disorders | ITGB2, ITGA1, ITGB1 | ITGB3 9/4885ITGAV 7/4885ITGA2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.